Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Carlee B Moser, Ph.D.

Title
Institution
Department
Address
Phone
Other Positions
Title
Institution
Department

Biography
education and training
University of New Hampshire, Durham, NHB.S.05/2007Statistics
Boston University, Boston, MAM.A.05/2009Biostatistics
Boston University, Boston, MAPhD05/2013Biostatistics

Overview
overview
Carlee Moser is a Senior Research Scientist at the Center for Biostatistics in AIDS Research within the Department of Biostatistics at the Harvard T. H. Chan School of Public Health. She has extensive experience in statistical methods in epidemiology, observational studies, and clinical trials. She has worked with investigators at the Framingham Heart Study on multiple projects to understand cardiovascular risk factors and biomarkers, and their relationship to health outcomes such as atrial fibrillation, stroke, and cardiovascular disease. Her primary role with in CBAR is as a senior statistician with the AIDS Clinical Trials Group (ACTG) where she has collaborated with clinical investigators on the development of clinical trial protocols, and has overseen the monitoring and analyses of studies. With her work with the ACTG she has served in a leadership role as the statistical representative on the End-Organ Disease and Inflammation Translation Science Group (EOD/iTSG) where she provides statistical review and support for the development of new proposals, as well as management of statistical resources. Her primary research interest are varied and include understanding mechanisms of sustained systemic inflammation and immune activation in HIV+ populations and metabolic complications of HIV, and statistical issues related to analyzing laboratory-based biomarker data.

Recently, she took on the role of lead statistician working on the Operation Warp Speed platform trial of potential outpatient treatments for COVID-19. This trial is a major initiative of a collaboration between NIH, FDA and pharmaceutical companies known as ACTIV (Accelerating COVID-19 Therapeutic Interventions and Vaccines). The aim is to evaluate candidate monoclonal antibodies, and other immunological and antiviral agents using a standardized protocol with an adaptive design, including a possibly seamless phase 2 to phase 3 trial component.
keywords

Featured Content
Twitter

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Hastie E, Moser C, Sun X, Lennox J, Hsue PY, Bosch RJ, Deeks S, Meneses MV, Lederman MM, Hunt P, Henrich TJ, Marconi VC, Gianella S. Effect of Immune-Modulatory Interventions on Asymptomatic Cytomegalovirus Shedding during Suppressive Antiretroviral Therapy. J Infect Dis. 2023 Mar 07. PMID: 36881933.
    Citations:    Fields:    
  2. Deo R, Choudhary MC, Moser C, Ritz J, Daar ES, Wohl DA, Greninger AL, Eron JJ, Currier JS, Hughes MD, Smith DM, Chew KW, Li JZ. Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection. Ann Intern Med. 2023 03; 176(3):348-354. PMID: 36802755.
    Citations:    Fields:    
  3. Li Y, Harrison LJ, Chew KW, Currier JS, Wohl DA, Daar ES, Evering TH, Wu R, Giganti M, Ritz J, Javan AC, Coombs RW, Moser C, Hughes MD, Eron JJ, Smith DM, Li JZ. Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019. Clin Infect Dis. 2023 02 18; 76(4):734-737. PMID: 36210483; PMCID: PMC9619579.
    Citations:    Fields:    Translation:HumansCells
  4. Taiwo BO, Chew KW, Moser C, Wohl DA, Daar ES, Li JZ, Greninger AL, Bausch C, Luke T, Hoover K, Neytman G, Giganti MJ, Olefsky M, Javan AC, Fletcher CV, Eron JJ, Currier JS, Hughes MD, Smith DM. Phase 2 safety and antiviral activity of SAB-185, a novel polyclonal antibody therapy for non-hospitalized adults with COVID-19. J Infect Dis. 2023 Jan 20. PMID: 36661240.
    Citations:    Fields:    
  5. Chew KW, Moser C, Daar ES, Wohl DA, Li JZ, Coombs RW, Ritz J, Giganti M, Javan AC, Li Y, Choudhary MC, Deo R, Malvestutto C, Klekotka P, Price K, Nirula A, Fischer W, Bala V, Ribeiro RM, Perelson AS, Fletcher CV, Eron JJ, Currier JS, Hughes MD, Smith DM. Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19. Nat Commun. 2023 Jan 19; 14(1):333. PMID: 36658128; PMCID: PMC9851732.
    Citations:    Fields:    
  6. Ramirez SI, Grifoni A, Weiskopf D, Parikh UM, Heaps A, Faraji F, Sieg SF, Ritz J, Moser C, Eron JJ, Currier JS, Klekotka P, Sette A, Wohl DA, Daar ES, Hughes MD, Chew KW, Smith DM, Crotty S. Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses. JCI Insight. 2022 12 22; 7(24). PMID: 36378539; PMCID: PMC9869965.
    Citations:    Fields:    Translation:HumansCells
  7. Moser C, Li JZ, Eron JJ, Aga E, Daar ES, Wohl DA, Coombs RW, Javan AC, Bender Ignacio RA, Jagannathan P, Ritz J, Sieg SF, Parikh UM, Hughes MD, Currier JS, Smith DM, Chew KW. Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19. Open Forum Infect Dis. 2022 Nov; 9(11):ofac618. PMID: 36467293; PMCID: PMC9709705.
    Citations:    
  8. Choudhary MC, Chew KW, Deo R, Flynn JP, Regan J, Crain CR, Moser C, Hughes MD, Ritz J, Ribeiro RM, Ke R, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Fletcher CV, Daar ES, Wohl DA, Eron JJ, Currier JS, Parikh UM, Sieg SF, Perelson AS, Coombs RW, Smith DM, Li JZ. Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial. Nat Microbiol. 2022 11; 7(11):1906-1917. PMID: 36289399; PMCID: PMC9675946.
    Citations:    Fields:    Translation:HumansCellsCTClinical Trials
  9. Smith DM, Li JZ, Moser C, Yeh E, Currier JS, Chew KW, Hughes MD. Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19. JAMA Netw Open. 2022 10 03; 5(10):e2238867. PMID: 36301549; PMCID: PMC9614575.
    Citations: 2     Fields:    Translation:Humans
  10. Chew KW, Moser C, Daar ES, Wohl DA, Li JZ, Coombs RW, Ritz J, Giganti M, Javan AC, Li Y, Choudhary MC, Deo R, Malvestutto C, Klekotka P, Price K, Nirula A, Fischer W, Bala V, Ribeiro RM, Perelson AS, Fletcher CV, Eron JJ, Currier JS, Hughes MD, Smith DM. Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19. Nat Commun. 2022 08 22; 13(1):4931. PMID: 35995785; PMCID: PMC9395368.
    Citations: 5     Fields:    Translation:HumansCells
  11. Deo R, Choudhary MC, Moser C, Ritz J, Daar ES, Wohl DA, Greninger AL, Eron JJ, Currier JS, Hughes MD, Smith DM, Chew KW, Li JZ. Viral and Symptom Rebound in Untreated COVID-19 Infection. medRxiv. 2022 Aug 02. PMID: 35982660; PMCID: PMC9387151.
    Citations:    
  12. Boucau J, Chew KW, Choudhary MC, Deo R, Regan J, Flynn JP, Crain CR, Hughes MD, Ritz J, Moser C, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Coombs RW, Fischer WA, Daar ES, Wohl DA, Eron JJ, Currier JS, Smith DM, Li JZ, Barczak AK. Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection. Cell Rep Med. 2022 07 19; 3(7):100678. PMID: 35793677; PMCID: PMC9213028.
    Citations: 6     Fields:    Translation:HumansCellsCTClinical Trials
  13. Koethe JR, Moser C, Brown TT, Stein JH, Kelesidis T, Dube M, Currier J, McComsey GA. Adipokines, Weight Gain and Metabolic and Inflammatory Markers After Antiretroviral Therapy Initiation: AIDS Clinical Trials Group (ACTG) A5260s. Clin Infect Dis. 2022 03 09; 74(5):857-864. PMID: 34117756; PMCID: PMC8906713.
    Citations: 1     Fields:    Translation:Humans
  14. Premeaux TA, Moser CB, McKhann A, Hoenigl M, Yeung ST, Pang APS, Corley MJ, Lederman MM, Landay AL, Gianella S, Ndhlovu LC. Monitoring Circulating Immune Checkpoint Proteins as Predictors of Non-AIDS Morbid Events in People With HIV Initiating Antiretroviral Therapy. Open Forum Infect Dis. 2022 Mar; 9(3):ofab570. PMID: 35146038; PMCID: PMC8826032.
    Citations: 1     
  15. Marconi VC, Moser C, Gavegnano C, Deeks SG, Lederman MM, Overton ET, Tsibris A, Hunt PW, Kantor A, Sekaly RP, Tressler R, Flexner C, Hurwitz SJ, Moisi D, Clagett B, Hardin WR, Del Rio C, Schinazi RF, Lennox JJ. Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2022 01 07; 74(1):95-104. PMID: 33693561; PMCID: PMC8752257.
    Citations: 19     Fields:    Translation:HumansCells
  16. Boucau J, Chew KW, Choudhary M, Deo R, Regan J, Flynn JP, Crain CR, Hughes MD, Ritz J, Moser C, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Coombs RW, Fischer WA, Daar ES, Wohl DA, Eron JJ, Currier JS, Smith DM, Li JZ, Barczak AK. Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection. medRxiv. 2021 Dec 30. PMID: 35018382; PMCID: PMC8750705.
    Citations: 1     
  17. Chew KW, Moser C, Daar ES, Wohl DA, Li JZ, Coombs R, Ritz J, Giganti M, Javan AC, Li Y, Malvestutto C, Klekotka P, Price K, Nirula A, Fischer W, Bala V, Ribeiro RM, Perelson AS, Fletcher CV, Eron JJ, Currier JS, Hughes MD, Smith DM. Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19. medRxiv. 2021 Dec 21. PMID: 34981077; PMCID: PMC8722620.
    Citations: 1     
  18. Premeaux TA, Moser CB, McKhann A, Hoenigl M, Laws EI, Aquino DL, Lederman MM, Landay AL, Gianella S, Ndhlovu LC. Plasma galectin-9 as a predictor of adverse non-AIDS events in persons with chronic HIV during suppressive antiretroviral therapy. AIDS. 2021 12 01; 35(15):2489-2495. PMID: 34366381; PMCID: PMC8631144.
    Citations: 1     Fields:    Translation:Humans
  19. Kousari A, Moser C, Olefsky M, Brown TT, Currier JS, McComsey GA, Scherzinger A, Stein JH, Lake JE, Erlandson KM. Poorer Muscle Quality and Quantity With ART Initiation Is Associated With Greater Inflammation and Immune Activation. J Acquir Immune Defic Syndr. 2021 12 01; 88(4):399-405. PMID: 34326283; PMCID: PMC8556226.
    Citations:    Fields:    Translation:Humans
  20. Choudhary MC, Chew KW, Deo R, Flynn JP, Regan J, Crain CR, Moser C, Hughes M, Ritz J, Ribeiro RM, Ke R, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Fletcher CV, Daar ES, Wohl DA, Eron JJ, Currier JS, Parikh UM, Sieg SF, Perelson AS, Coombs RW, Smith DM, Li JZ. Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy. medRxiv. 2021 Sep 15. PMID: 34545376; PMCID: PMC8452115.
    Citations:    
  21. Yola IM, Moser C, Duncan MS, Schwedhelm E, Atzler D, Maas R, Hannemann J, Böger RH, Vasan RS, Xanthakis V. Associations of circulating dimethylarginines with the metabolic syndrome in the Framingham Offspring study. PLoS One. 2021; 16(9):e0254577. PMID: 34492019.
    Citations: 1     Fields:    Translation:Humans
  22. El Kamari V, Rodriguez K, Moser C, Currier JS, Kelesidis T, Stein JH, Brown TT, Howell SK, Beisswenger PJ, McComsey GA. Advanced Glycation End Products Associated With Cardiometabolic Biomarkers in Treated Human Immunodeficiency Virus Infection. Open Forum Infect Dis. 2021 Oct; 8(10):ofab423. PMID: 34631914; PMCID: PMC8496763.
    Citations: 1     
  23. Hurwitz SJ, Tao S, Gavegnano C, Jiang Y, Tressler RL, Tsibris A, Del Rio C, Overton ET, Lederman MM, Kantor A, Moser C, Kohler JJ, Lennox J, Marconi VC, Flexner CW, Schinazi RF. Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study. J Clin Pharmacol. 2021 12; 61(12):1555-1566. PMID: 34169526; PMCID: PMC8599628.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  24. White LF, Moser CB, Thompson RN, Pagano M. Statistical Estimation of the Reproductive Number From Case Notification Data. Am J Epidemiol. 2021 04 06; 190(4):611-620. PMID: 33034345.
    Citations: 8     Fields:    Translation:HumansPHPublic Health
  25. Debroy P, Lake JE, Moser C, Olefsky M, Erlandson KM, Scherzinger A, Stein JH, Currier JS, Brown TT, McComsey GA. Antiretroviral Therapy Initiation Is Associated With Decreased Visceral and Subcutaneous Adipose Tissue Density in People Living With Human Immunodeficiency Virus. Clin Infect Dis. 2021 03 15; 72(6):979-986. PMID: 32107532.
    Citations: 5     Fields:    Translation:HumansCells
  26. Garza J, Moser C, Kitch DW, Currier JS, Dubé MP, Stein J, McComsey G, Brown TT. Short Communication: Impact of Fat Changes on the Effect of Protease Inhibitors on Lumbar Spine Bone Mineral Density Changes with Antiretroviral Therapy Initiation. AIDS Res Hum Retroviruses. 2020 10; 36(10):831-834. PMID: 32623904; PMCID: PMC7548021.
    Citations:    Fields:    Translation:Humans
  27. Gianella S, Moser C, Vitomirov A, McKhann A, Layman L, Scott B, Caballero G, Lada S, Bosch RJ, Hoenigl M, Lurain N, Landay A, Lederman MM, Hunt PW, Smith D. Presence of asymptomatic cytomegalovirus and Epstein--Barr virus DNA in blood of persons with HIV starting antiretroviral therapy is associated with non-AIDS clinical events. AIDS. 2020 05 01; 34(6):849-857. PMID: 32271250; PMCID: PMC7239326.
    Citations: 15     Fields:    Translation:HumansCells
  28. Trevillyan JM, Moser C, Currier JS, Sallam T. Immune Biomarkers in the Prediction of Future Myocardial Infarctions in People With Human Immunodeficiency Virus. Clin Infect Dis. 2020 04 10; 70(8):1764-1767. PMID: 31414117.
    Citations:    Fields:    Translation:HumansCells
  29. Krown SE, Moser CB, MacPhail P, Matining RM, Godfrey C, Caruso SR, Hosseinipour MC, Samaneka W, Nyirenda M, Busakhala NW, Okuku FM, Kosgei J, Hoagland B, Mwelase N, Oliver VO, Burger H, Mngqibisa R, Nokta M, Campbell TB, Borok MZ. Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. Lancet. 2020 04 11; 395(10231):1195-1207. PMID: 32145827; PMCID: PMC7236082.
    Citations: 19     Fields:    Translation:Humans
  30. Gianella S, Moser C, Vitomirov A, McKhann A, Layman L, Scott B, Caballero G, Lada S, Bosch RJ, Hoenigl M, Lurain N, Landay A, Lederman MM, Hunt PW, Smith D. Presence of asymptomatic CMV and EBV DNA in blood of persons with HIV starting antiretroviral therapy are associated with non-AIDS clinical events. AIDS. 2020 Jan 30. PMID: 32004204.
    Citations:    
  31. Dirajlal-Fargo S, Moser C, Rodriguez K, El-Kamari V, Funderburg NT, Bowman E, Brown TT, Hunt PW, Currier J, McComsey GA. Changes in the Fungal Marker ß-D-Glucan After Antiretroviral Therapy and Association With Adiposity. Open Forum Infect Dis. 2019 Nov; 6(11):ofz434. PMID: 31737737; PMCID: PMC6847395.
    Citations: 9     
  32. Lake JE, Moser C, Johnston L, Magyar C, Nelson SD, Erlandson KM, Brown TT, McComsey GA. CT Fat Density Accurately Reflects Histologic Fat Quality in Adults With HIV On and Off Antiretroviral Therapy. J Clin Endocrinol Metab. 2019 10 01; 104(10):4857-4864. PMID: 31329901; PMCID: PMC6733493.
    Citations: 7     Fields:    Translation:HumansCells
  33. Hoenigl M, Moser CB, Funderburg N, Bosch R, Kantor A, Zhang Y, Eugen-Olsen J, Finkelman M, Reiser J, Landay A, Moisi D, Lederman MM, Gianella S. Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy-mediated Viral Suppression. Clin Infect Dis. 2019 08 01; 69(4):676-686. PMID: 30418519.
    Citations: 34     Fields:    Translation:Humans
  34. Kay A, Moser C, McKhann A, Vargas M, Porrachia M, Gianella S, Hoenigl M. Soluble suppression of tumorigenicity 2 levels are not predictive of non-AIDS events during antiretroviral therapy-mediated viral suppression. AIDS. 2019 07 01; 33(8):1397-1399. PMID: 31157664; PMCID: PMC6561120.
    Citations: 1     Fields:    Translation:Humans
  35. El Kamari V, Moser C, Hileman CO, Currier JS, Brown TT, Johnston L, Hunt PW, McComsey GA. Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral Therapy. Clin Infect Dis. 2019 04 08; 68(8):1394-1401. PMID: 30137242; PMCID: PMC6599164.
    Citations: 16     Fields:    Translation:Humans
  36. Gianella S, Marconi VC, Berzins B, Benson CA, Sax P, Fichtenbaum CJ, Wilkin T, Vargas M, Deng Q, Oliveira MF, Moser C, Taiwo BO. Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy. J Acquir Immune Defic Syndr. 2018 12 15; 79(5):e112-e114. PMID: 30383591; PMCID: PMC6231952.
    Citations: 4     Fields:    Translation:HumansCells
  37. Bhagwat P, Ofotokun I, McComsey GA, Brown TT, Moser C, Sugar CA, Currier JS. Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race. Open Forum Infect Dis. 2018 Nov; 5(11):ofy201. PMID: 30465010; PMCID: PMC6239079.
    Citations: 22     
  38. Kelesidis T, Moser CB, Johnston E, Stein JH, Dube MP, Yang OO, McComsey GA, Currier JS, Brown TT. Brief Report: Changes in Plasma RANKL-Osteoprotegerin in a Prospective, Randomized Clinical Trial of Initial Antiviral Therapy: A5260s. J Acquir Immune Defic Syndr. 2018 07 01; 78(3):362-366. PMID: 29533303; PMCID: PMC5997510.
    Citations: 2     Fields:    Translation:Humans
  39. Taiwo BO, Marconi VC, Berzins B, Moser CB, Nyaku AN, Fichtenbaum CJ, Benson CA, Wilkin T, Koletar SL, Colasanti J, Acosta EP, Li JZ, Sax PE. Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. Clin Infect Dis. 2018 05 17; 66(11):1794-1797. PMID: 29293895; PMCID: PMC5961309.
    Citations: 28     Fields:    Translation:HumansCells
  40. Bhagwat P, Ofotokun I, McComsey GA, Brown TT, Moser C, Sugar CA, Currier JS. Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes. Antivir Ther. 2017; 22(7):577-586. PMID: 28248190; PMCID: PMC5610106.
    Citations: 9     Fields:    Translation:Humans
  41. Moser CB, White LF. Estimating age-specific reproductive numbers-A comparison of methods. Stat Methods Med Res. 2018 07; 27(7):2050-2059. PMID: 28571521.
    Citations: 2     Fields:    Translation:HumansCellsPHPublic Health
  42. Kelesidis T, Tran TTT, Brown TT, Moser C, Ribaudo HJ, Dube MP, Yang OO, McComsey GA, Stein JH, Currier JS. Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s. Antivir Ther. 2017; 22(2):113-126. PMID: 27661466; PMCID: PMC5364070.
    Citations: 6     Fields:    Translation:HumansCells
  43. Dirajlal-Fargo S, Moser C, Brown TT, Kelesidis T, Dube MP, Stein JH, Currier J, McComsey GA. Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s. Open Forum Infect Dis. 2016 Sep; 3(3):ofw174. PMID: 27704026.
    Citations: 16     
  44. Kelesidis T, Moser C, Stein JH, Brown TT, Tran TT, Ribaudo HJ, Dube MP, Yang OO, Currier JS, McComsey GA. Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. J Infect Dis. 2016 09 01; 214(5):748-52. PMID: 27354367; PMCID: PMC4978379.
    Citations: 6     Fields:    Translation:HumansCells
  45. McComsey GA, Moser C, Currier J, Ribaudo HJ, Paczuski P, Dubé MP, Kelesidis T, Rothenberg J, Stein JH, Brown TT. Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s. Clin Infect Dis. 2016 Apr 01; 62(7):853-62. PMID: 26797215.
    Citations: 75     Fields:    Translation:Humans
  46. Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, Yang O, Dubé MP, Murphy RL, Stein JH, McComsey GA. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. J Infect Dis. 2015 Oct 15; 212(8):1241-9. PMID: 25948863; PMCID: PMC4577040.
    Citations: 56     Fields:    Translation:HumansCells
  47. Kelesidis T, Tran TT, Stein JH, Brown TT, Moser C, Ribaudo HJ, Dube MP, Murphy R, Yang OO, Currier JS, McComsey GA. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. Clin Infect Dis. 2015 Aug 15; 61(4):651-60. PMID: 25904376.
    Citations: 68     Fields:    Translation:Humans
  48. Moser CB, Gupta M, Archer BN, White LF. The impact of prior information on estimates of disease transmissibility using Bayesian tools. PLoS One. 2015; 10(3):e0118762. PMID: 25793993; PMCID: PMC4368801.
    Citations: 8     Fields:    Translation:HumansCellsPHPublic Health
  49. Sinner MF, Stepas KA, Moser CB, Krijthe BP, Aspelund T, Sotoodehnia N, Fontes JD, Janssens AC, Kronmal RA, Magnani JW, Witteman JC, Chamberlain AM, Lubitz SA, Schnabel RB, Vasan RS, Wang TJ, Agarwal SK, McManus DD, Franco OH, Yin X, Larson MG, Burke GL, Launer LJ, Hofman A, Levy D, Gottdiener JS, Kääb S, Couper D, Harris TB, Astor BC, Ballantyne CM, Hoogeveen RC, Arai AE, Soliman EZ, Ellinor PT, Stricker BH, Gudnason V, Heckbert SR, Pencina MJ, Benjamin EJ, Alonso A. B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. Europace. 2014 Oct; 16(10):1426-33. PMID: 25037055.
    Citations: 74     Fields:    Translation:Humans
  50. Magnani JW, Moser CB, Murabito JM, Sullivan LM, Wang N, Ellinor PT, Vasan RS, Benjamin EJ, Coviello AD. Association of sex hormones, aging, and atrial fibrillation in men: the Framingham Heart Study. Circ Arrhythm Electrophysiol. 2014 Apr; 7(2):307-12. PMID: 24610804.
    Citations: 30     Fields:    Translation:Humans
  51. Lubitz SA, Moser C, Sullivan L, Rienstra M, Fontes JD, Villalon ML, Pai M, McManus DD, Schnabel RB, Magnani JW, Yin X, Levy D, Pencina MJ, Larson MG, Ellinor PT, Benjamin EJ. Atrial fibrillation patterns and risks of subsequent stroke, heart failure, or death in the community. J Am Heart Assoc. 2013 Sep 03; 2(5):e000126. PMID: 24002369.
    Citations: 26     Fields:    Translation:Humans
  52. Schnabel RB, Rienstra M, Sullivan LM, Sun JX, Moser CB, Levy D, Pencina MJ, Fontes JD, Magnani JW, McManus DD, Lubitz SA, Tadros TM, Wang TJ, Ellinor PT, Vasan RS, Benjamin EJ. Risk assessment for incident heart failure in individuals with atrial fibrillation. Eur J Heart Fail. 2013 Aug; 15(8):843-9. PMID: 23594831.
    Citations: 38     Fields:    Translation:Humans
  53. Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB, Sinner MF, Sotoodehnia N, Fontes JD, Janssens AC, Kronmal RA, Magnani JW, Witteman JC, Chamberlain AM, Lubitz SA, Schnabel RB, Agarwal SK, McManus DD, Ellinor PT, Larson MG, Burke GL, Launer LJ, Hofman A, Levy D, Gottdiener JS, Kääb S, Couper D, Harris TB, Soliman EZ, Stricker BH, Gudnason V, Heckbert SR, Benjamin EJ. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013 Mar 18; 2(2):e000102. PMID: 23537808; PMCID: PMC3647274.
    Citations: 318     Fields:    Translation:Humans
  54. Magnani JW, Moser CB, Murabito JM, Nelson KP, Fontes JD, Lubitz SA, Sullivan LM, Ellinor PT, Benjamin EJ. Age of natural menopause and atrial fibrillation: the Framingham Heart Study. Am Heart J. 2012 Apr; 163(4):729-34. PMID: 22520541; PMCID: PMC3334861.
    Citations: 13     Fields:    Translation:Humans
  55. Dumitriu A, Moser C, Hadzi TC, Williamson SL, Pacheco CD, Hendricks AE, Latourelle JC, Wilk JB, Destefano AL, Myers RH. Postmortem Interval Influences a-Synuclein Expression in Parkinson Disease Brain. Parkinsons Dis. 2012; 2012:614212. PMID: 22530163.
    Citations: 9     
  56. Moser C, Gupta M. A generalized hidden Markov model for determining sequence-based predictors of nucleosome positioning. Stat Appl Genet Mol Biol. 2012 Jan 06; 11(2). PMID: 22499697.
    Citations: 1     Fields:    Translation:AnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: SPH faculty should contact Faculty Affairs at facultyaffairshsph.harvard.edu).
Moser's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (181)
Explore
_
Co-Authors (17)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
© 2023 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.